Patents Represented by Attorney Daniel A. Pearson

Find this attorney in the Justia Lawyer Directory

  • Inhibitors of phosphatidylinositol 3-kinase
    Patent number: 8344153
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: January 1, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin Michael Cottrell, Alex Aronov, Robert J. Davies, Jon H. Come, David Messersmith, Jinwang Xu, Upul Keerthi Bandarage, Jingrong Cao
  • Triazolothiadiazole inhibitor of c-Met protein kinase
    Patent number: 8343998
    Abstract: The present invention relates to compound 1, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising Compound 1 and methods of using the compositions in the treatment of proliferative disorders.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: January 1, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David J. Lauffer, Pan Li, Dean Shannon, Jianglin Liang
  • C-met protein kinase inhibitors
    Patent number: 8278306
    Abstract: Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: October 2, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Jingrong Cao, Upul Keerthi Bandarage, Jon H. Come, Craig Marhefka
  • Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase
    Patent number: 8269012
    Abstract: The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: September 18, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Lauffer, Pan Li, Kira McGinty
  • Inhibitors of C-MET and uses thereof
    Patent number: 8268818
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: September 18, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Tiansheng Wang, Jeremy Green, Brian Ledford, François Maltais, Andreas P. Termin, Mark Cornebise, Jonathan Parsons, Adam Tanner, James Westcott
  • Tri-cyclic pyrazolopyridine kinase inhibitors
    Patent number: 8268999
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: September 18, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alex Aronov, Jon H. Come, Kevin Michael Cottrell, Arnaud Le Tiran, Valerie Marone, Gabriel Martinez Botella, David Messersmith, Emilie Porter Huck, Ronald Lee Grey, Jr.
  • Lupane derivatives useful for treating HIV
    Patent number: 8269026
    Abstract: The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.
    Type: Grant
    Filed: July 3, 2010
    Date of Patent: September 18, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Christophe Moinet, Liliane Halab, Nathalie Turcotte, Monica Bubenik, Marc Courchesne, Carl Poisson, Oswy Z. Pereira, Paul Nguyen-Ba, Bingcan Liu, Nathalie Chauret, Caroline Cadilhac, Laval Chan Chun Kong
  • Substituted pyrazole inhibitors of c-Met protein kinase
    Patent number: 8269013
    Abstract: The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: September 18, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Pan Li, Nathan Waal, Steven Ronkin, Qing Tang, David Lauffer
  • Inhibitors of c-Met protein kinase
    Patent number: 8263776
    Abstract: The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: September 11, 2012
    Inventors: David Lauffer, Pan Li
  • Aminopyrazole triazolothiadiazole inhibitor of c-Met protein kinase
    Patent number: 8263777
    Abstract: The present invention relates to anhydrous and hydrated forms of Compound 1, which are useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: September 11, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David J. Lauffer, Pan Li, Stefanie Roeper, Shereen Ibrahim, Anuj K. Kuldipkumar, Yi Shi, David B. Miller, Jr.
  • c-MET protein kinase inhibitors
    Patent number: 8232406
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: July 31, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David J. Lauffer, Robert J. Davies, Dean Stamos, Alexander Aronov, David D. Deininger, Ronald Grey, Jr., Jinwang Xu, Pan Li, Brian Ledford, Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Kira McGinty
  • Triazolothiadiazole inhibitor of c-Met protein kinase
    Patent number: 8217056
    Abstract: The present invention relates to compound 1, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising Compound 1 and methods of using the compositions in the treatment of proliferative disorders.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: July 10, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Lauffer, Pan Li, Dean Shannon, Jianglin Liang
  • Selective inhibitors of rock protein kinase and uses thereof
    Patent number: 8058271
    Abstract: Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: November 15, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Jingrong Cao, Upul Bandarage, Jon Come, Craig Marhefka
  • Inhibitors of c-Met and uses thereof
    Patent number: 7998987
    Abstract: The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: August 16, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Lauffer, Alex Aronov, Pan Li, David Deininger, Kira McGinty, Dean Stamos, Jon Come, Michelle Stewart
  • Diaminotriazoles useful as inhibitors of protein kinases
    Patent number: 7902239
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 9, 2007
    Date of Patent: March 8, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Albert C. Pierce, Michael Arnost, Robert J. Davies, Cornelia J. Forster, Vincent Galullo, Ronald Grey, Jr., Mark Ledeboer, Shi-Kai Tian, Jinwang Xu, Hayley Binch, Brian Ledford, David Messersmith, Suganthi Nanthakumar, Andrew Jayaraj, Greg Henkel, Francesco G. Salituro, Jian Wang
  • c-MET protein kinase inhibitors
    Patent number: 7872031
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: January 18, 2011
    Assignee: Vertex Pharmaceuticals incorporated
    Inventors: David J. Lauffer, Robert J. Davies, Dean Stamos, Alexander Aronov, David D. Deininger, Ronald Grey, Jr., Jinwang Xu, Pan Li, Brian Ledford, Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Kira McGinty
  • Inhibitors of c-Met and uses thereof
    Patent number: 7728017
    Abstract: The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: June 1, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David J. Lauffer, Alexander Aronov, Pan Li, David D. Deininger, Kira McGinty, Dean Stamos, Jon H. Come, Michelle Stewart
  • Triazoles useful as inhibitors of protein kinases
    Patent number: 7645775
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: January 12, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert Davies, Cornelia Forster, Michael Arnost, Jian Wang
  • Aminotriazole compounds useful as inhibitors of protein kinases
    Patent number: 7598245
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: October 6, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael J. Arnost, Guy W. Bemis, Robert J. Davies, Cornelia J. Forster, Ronald Grey, Jr., Mark W. Ledeboer, Brian Ledford, Craig Marhefka, David Messersmith, Albert C. Pierce, Francesco G. Salituro, Jian Wang
  • Compositions useful as inhibitors of protein kinases
    Patent number: 7547794
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: June 16, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Alex Aronov, Albert C. Pierce